By automating tasks and increasing precision, new liquid handling technologies serve to streamline workflows and free up the hands of researchers to focus on the important stuff – the science.
Hardy Diagnostics is a 100% employee-owned company that is licensed by the FDA as a medical device manufacturer, and its quality management system is ISO 13485 certified. Hardy Diagnostics has been helping people live healthier lives since 1980. Our microbiology products are used all over the world to diagnose and prevent disease.
New products and technologies are helping to arm scientists and medical professionals – providing the insight needed in the fight against this unprecedented viral disease.
Bold innovations in sample collection, point of care detection, immunity profiling and other applications are adding new firepower in the fight against COVID-19.
Companies have stepped forward with innovative products in the areas of personal protective equipment, testing and diagnostics, safety and automation, and others in the fight against the COVID-19 pandemic.
The Emerging Trends in Infectious Disease Interactive Infographic is a living resource, staying current with diagnostic, protective, and therapeutic developments in the vitally important area. This post serves as a chronology of the infographic, citing ongoing developments in the areas of: Detection and Containment, Diagnosis and Treatment, Laboratory Equipment, and Prevention and Surveillance.
Challenges with the approval of COVID-19 test diagnostics uncovered serious process issues that are now being resolved in order to contain the current outbreak and to fight future pathogens.
Digital PCR or dPCR extends where qPCR falls short, namely in the accuracy and precision of absolute quantitation and the manner in which target DNA is measured. Here we explore details behind the application of this powerful technology.
Harnessing the power of next generation sequencing technologies, in combined approaches, can improve the speed, accuracy, and quality of diagnostic results.
2017 has seen the launch of several breakthrough clinical LC-MS technologies, driving new areas of clinical exploration and anticipation for what's to come.